The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: mutant DNA polymerases. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
80+ innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 730,000 patents, there are 80+ innovation areas that will shape the future of the industry.
Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Peptide pharmacophores, antibody-drug conjugates and neuroprotective drugs are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are amyloid precursor targeted therapies and modified vector HIV-1 vaccines, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Mutant DNA polymerases is a key innovation area in the pharmaceutical industry
Mutant DNA polymerases, also known as engineered or modified DNA polymerases, are variants of the naturally occurring enzymes that have been altered to possess specific characteristics or functionalities. These mutant polymerases have been widely used in various scientific and biotechnological applications due to their enhanced properties and abilities. Some common types of mutant DNA polymerases such as high-fidelity DNA polymerases like Pfu DNA polymerase, possess a proofreading ability that greatly reduces the error rate during DNA replication. Thermostable DNA polymerases, such as Taq DNA polymerase, are derived from thermophilic microorganisms and can withstand high temperatures without losing their activity. Reverse transcriptase are mutant DNA polymerases that can synthesize complementary DNA (cDNA) from RNA templates. Site-directed mutagenesis polymerases, such as PfuTurbo DNA polymerase, are specifically engineered to introduce targeted mutations into DNA sequences.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 385+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of mutant DNA polymerases.
Key players in mutant DNA polymerases – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
F. Hoffmann-La Roche is one of the leading patent filers in mutant DNA polymerases. As part of Roche, CustomBiotech is manufacturing and supplying variety of mutant DNA polymerases for biopharma and diagnostics businesses. Thermo Fisher Scientific and GemVax & KAEL are some of the other key patent filers in mutant DNA polymerases.
In terms of application diversity, Toyobo leads the pack, while Singular Genomics Systems and Genecast stood in the second and third positions, respectively.
By means of geographic reach, NMS Group held the top position, followed by Compagnie Merieux Alliance and OncoPlex Diagnostics.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
